Ashling Wahner

Associate Editor, OncLive

Ashling Wahner joined MJH Life Sciences in 2022. She produces OncLive's podcast, OncLive On Air, and helps ensure timely publication of news content and announcements from the FDA approval pipeline. She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: awahner@mjhlifesciences.com

Articles

Daratumumab-Containing Regimens Display PFS Benefit Across Myeloma Subgroups

September 1st 2022

Daratumumab combinations elicited significant progression-free survival, overall survival, overall response rate, and minimal residual disease–negativity benefits vs control in pretreated patients with relapsed or refractory multiple myeloma across clinically relevant subgroups.

Subcutaneous Isatuximab Elicits Comparable Efficacy, Safety to IV Formulation in Relapsed/Refractory Myeloma

August 31st 2022

Subcutaneous administration of isatuximab through a syringe pump or on-body delivery system demonstrated similar efficacy and safety compared with intravenous isatuximab when combined with pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma.

Multidisciplinary Management Stands at the Forefront of Breast Cancer Treatment

August 29th 2022

Judy C. Boughey, MD, shares criteria for omission of sentinel lymph node surgery, the importance of not altering treatment based on identification of variants of uncertain significance, and the potential value of trastuzumab deruxtecan in HER2-low metastatic breast cancer.

Emerging Data are Expanding Treatment Options, Extending Survival Across Breast Cancer Subtypes

August 29th 2022

Matthew P. Goetz, MD, discusses overall survival data with ribociclib and abemaciclib in estrogen receptor–positive, HER2-negative disease; the role of adjuvant pembrolizumab in patients with triple-negative breast cancer; and the efficacy of PARP inhibitors in earlier settings.

Ixazomib Regimen Induces High Response Rates, Proves Tolerable in Relapsed/Refractory Multiple Myeloma

August 26th 2022

The addition of ixazomib to daratumumab, pomalidomide, and dexamethasone has elicited deep and durable response rates with a manageable safety profile as salvage therapy in patients with relapsed/refractory multiple myeloma.

Maintenance With Niraparib and Ipilimumab Demonstrates PFS Benefit in Pancreatic Cancer

August 23rd 2022

Niraparib plus ipilimumab maintenance therapy elicited encouraging progression-free survival results in patients with advanced pancreatic cancer who achieved a stable response to platinum-based chemotherapy.

Durvalumab Plus Tremelimumab Elicits Favorable PFS Rates in Advanced Sarcomas

August 23rd 2022

The combination of durvalumab and tremelimumab demonstrated positive progression-free survival and overall survival rates with expected toxicity data in patients with advanced or metastatic soft tissue and bone sarcomas.

Perioperative Immunotherapy Demonstrates Promising pCR Rates in dMMR/MSI-H Gastric and GEJ Cancer

August 22nd 2022

Neoadjuvant nivolumab plus ipilimumab followed by adjuvant nivolumab elicited positive pathologic complete response rates in patients with locally advanced resectable mismatch repair–deficient and/or microsatellite instability–high gastric or gastroesophageal junction adenocarcinoma.

Concurrent Galunisertib and Neoadjuvant Chemoradiotherapy Improves CR Rates in Rectal Cancer

August 19th 2022

The addition of galunisertib to neoadjuvant chemoradiotherapy improved complete response rates in patients with locally advanced rectal cancer, according to findings from a phase 2 study.

Elotuzumab Plus Pomalidomide and Dexamethasone Displays Sustained OS Benefit in Relapsed/Refractory Multiple Myeloma

August 18th 2022

Elotuzumab plus pomalidomide and dexamethasone demonstrated a significant improvement in overall survival compared with pomalidomide and dexamethasone alone in patients with relapsed/refractory multiple myeloma who previously received treatment with lenalidomide and a proteasome inhibitor.

Immunotherapy Combinations Launch Into Earlier Lines and Signal Success in Metastatic Solid Tumors

August 17th 2022

Successful, established immunotherapies that have been approved for use in the metastatic setting are rapidly moving forward into the adjuvant and neoadjuvant settings, and novel agents are emerging in later lines.

Maintenance Rituximab Prolongs Time to Next Treatment, OS in MCL

August 17th 2022

Maintenance rituximab following first-line bendamustine plus rituximab or a combination of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone prolonged first-line treatment benefits and improved survival outcomes vs either induction regimen alone.

Teclistamab Demonstrates Durable Response Rates in BCMA-Pretreated Multiple Myeloma

August 15th 2022

Saad Z. Usmani, MD, MBA, FACP, discusses key efficacy findings that support the use of teclistamab in patients with relapsed/refractory multiple myeloma who have had prior exposure to BCMA-targeted agents.

Adagrasib Elicits Responses in KRAS G12C–Mutant NSCLC

August 12th 2022

Joshua K. Sabari, MD, discusses the significance of adagrasib as an agent with favorable central nervous system penetration and importance of performing next-generation sequencing in all patients with non–small cell lung cancer to detect KRAS G12C mutations.

Combination Therapies and HER2-Targeted Agents Signal Favorable Responses in Gastrointestinal Cancers

August 12th 2022

Anne M. Noonan, MBBCh, discusses prominent new therapies in hepatocellular carcinoma, the benefits of immunotherapy in gastric cancer, chemotherapy developments in pancreatic cancer, and the importance of considering HER2-targeted therapy in metastatic colorectal cancer.

CC-99282 Demonstrates Manageable Safety Profile, Elicits Favorable Responses in Non-Hodgkin Lymphoma

August 11th 2022

Jean-Marie Michot, MD, discusses the methods and rationale for the CC-99282-NHL-001 study.

Neoadjuvant mFOLFIRINOX Exceeds Historical OS Rates in Pancreatic Cancer

August 10th 2022

Matthew H. G. Katz, MD, CMQ, FACS, FASCO, discusses the use of neoadjuvant mFOLFIRINOX in patients with borderline resectable pancreatic cancer.

Neoadjuvant Adagrasib Alone or With Nivolumab May Improve pCR Rates in NSCLC

August 6th 2022

Neoadjuvant adagrasib as monotherapy or in combination with nivolumab may elicit improved pathologic complete response rates in patients with resectable, KRAS G12C–mutated non–small cell lung cancer, according to the rationale for the phase 2 Neo-KAN study.

Biomarker Testing Provides a Way Forward for Increasingly Accurate Lung Cancer Diagnosis and Management

August 4th 2022

Giuseppe Lo Russo, MD, PhD, highlights the future role of liquid biopsy, the evolution of targeted therapies for KRAS G12C mutations, data to look forward to with EGFR-targeted agents, and the striking effects the COVID-19 pandemic has had on the mortality rates of patients with lung cancer.

Poziotinib Elicits Encouraging, Insertion Location–Specific Response Rates in EGFR Exon 20–Mutant NSCLC

August 4th 2022

Yasir Y. Elamin, MD, explained the rationale, design, and key findings of a phase 2 study evaluating poziotinib in patients with EGFR exon 20–mutated non–small cell lung cancer.